StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for PVLA yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $114.24 | $105.05 | -8.04% | 0.3M |
| 05-19 | $103.34 | $109.20 | +5.67% | 0.2M |
| 05-20 | $110.99 | $115.50 | +4.06% | 0.2M |
| 05-21 | $114.21 | $115.92 | +1.50% | 0.2M |
| 05-22 | $116.78 | $113.99 | -2.39% | 0.1M |
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2019 2019-12-31 | Q3 2019 2019-09-30 | Q2 2019 2019-06-30 | Q1 2019 2019-03-31 |
|---|---|---|---|---|
Revenue | $43.65M | $26.97M | $12.47M | $7.53M |
Operating Income | $-27.16M | $-25.83M | $-22.91M | $-10.68M |
Net Income | $-25.47M | $-24.70M | $-22.11M | $-10.35M |
EPS (Diluted) | Not available | Not available | Not available | Not available |
Total Assets | $141.10M | $116.75M | $130.84M | $131.05M |
Total Liabilities | $89.75M | $96.11M | $111.36M | $100.89M |
Cash & Equivalents | $62.26M | $46.07M | $54.90M | $52.09M |
Free Cash Flow OCF − CapEx | $-54.93M | $-39.78M | $-26.89M | $-15.23M |
Shares Outstanding | 55.21M | 49.39M | 49.26M | 49.15M |